Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07323784 · ClinicalTrials.gov registry record · Phase 2
A Study of NTX-1472 in Social Anxiety Disorder
A Phase 2 study of Social Anxiety Disorder (SAD), sponsored by Newleos Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 11
- Study locations
NCT07323784: Recruiting Phase 2 study of Social Anxiety Disorder (SAD), sponsored by Newleos Therapeutics.
NCT07323784 is a Phase 2 study of Social Anxiety Disorder (SAD) that is actively recruiting participants, run by Newleos Therapeutics. The registered enrollment target is 100 participants, below the 183-participant average among 5 other Social Anxiety Disorder (SAD) trials with a reported enrollment target (45% lower). The trial reports 11 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07323784, a Phase 2 study of Social Anxiety Disorder (SAD), is actively recruiting participants, sponsored by Newleos Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 11
- Study locations
Study Summary
The primary goal of this Phase 2 clinical trial is to determine the effects of a novel V1a receptor antagonist (NTX-1472) in adults with Social Anxiety Disorder (SAD). The main questions this trial aims to answer are: * Is NTX-1472 safe and well tolerated in adults with SAD? * How effectively does NTX-1472 treat adults with SAD? Researchers will compare the effects of NTX-1472 with matching placebo (a look-alike capsule that contains no drug). Participants will: * Take NTX-1472 or matching placebo every day for 8 weeks * Visit the clinic 6 times over the course of 14 weeks for checkups and tests
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NTX-1472
Study Locations (11)
California
- SOAR Clinical Study Site - Encino
- SOAR Clinical Study Site - Los Angeles
- SOAR Clinical Study Site - Oceanside
- SOAR Clinical Study Site - San Jose
Florida
- SOAR Clinical Study Site - Jacksonville
- SOAR Clinical Study Site - Tampa
Arizona
- SOAR Clinical Study Site - Pheonix
Massachusetts
- SOAR Clinical Study Site - Boston
New York
- SOAR Clinical Study Site - Brooklyn
Tennessee
- SOAR Clinical Study Site - Memphis
Texas
- SOAR Clinical Study Site - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-12-09 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
What NCT07323784 shows while recruiting
NCT07323784 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 183-participant average among 5 other Social Anxiety Disorder (SAD) trials with a reported enrollment target (45% lower).
The record links to 1 condition, with Social Anxiety Disorder (SAD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07323784 lists 11 locations in 7 states (California, Florida, Arizona).
Frequently Asked Questions
What is clinical trial NCT07323784 about?
NCT07323784 is a clinical study titled "A Study of NTX-1472 in Social Anxiety Disorder". The primary goal of this Phase 2 clinical trial is to determine the effects of a novel V1a receptor antagonist (NTX-1472) in adults with Social Anxiety Disorder (SAD). The main questions this trial aims to answer are: * Is NTX-1472 safe and well tolerated in adults with SAD? * How effectively does ...
What is the current status of trial NCT07323784?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-12-09. Estimated completion is 2027-01.
What conditions does trial NCT07323784 study?
This clinical trial studies the following conditions: Social Anxiety Disorder (SAD).
What interventions are being tested in trial NCT07323784?
The interventions under investigation include: Placebo (DRUG), NTX-1472 (DRUG).
Who is sponsoring clinical trial NCT07323784?
This trial is sponsored by Newleos Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07323784 being conducted?
This trial has 11 study locations across Arizona, California, Florida, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Social Anxiety Disorder (SAD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Stepped Care Treatment for Anxiety Resilience
RECRUITING · NA
-
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
RECRUITING · Phase 3
-
Nefazodone in the Treatment of Social Phobia
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI